A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-2
PGR Mda, MA Phdb, JRB Mdc, CCM Phdd, MAD Mde, CTH Mdf, JKM Phdg, AOM Phdh, RZOM Phdi, Md HQj, MSR Mdk, ARM Phdl, DW Mdm, ZZ Phdb, VHM Phdn, JKM Phdb
a Dana-Farber Cancer Institute, Boston, United States
b Bristol Myers Squibb, Princeton, United States
c Institute for Myeloma and Bone Cancer Research, West Hollywood, United States
d Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
e National and Kapodistrian University of Athens, Athens, Greece
f Odense University Hospital, Odense, Denmark
g Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan
h Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
i Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States
j St. Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Australia
k Universitätsklinikum Heidelberg, Heidelberg, Germany
l Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
m Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada
n Clínica São Germano, São Paulo, Brazil
Ver másLido
235
Vezesque se leu este artigo
144
Total PDF
91
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2024 Maio | 7 | 13 | 20 |
| 2024 Abril | 14 | 16 | 30 |
| 2024 Março | 20 | 27 | 47 |
| 2024 Fevereiro | 13 | 25 | 38 |
| 2024 Janeiro | 12 | 13 | 25 |
| 2023 Dezembro | 12 | 25 | 37 |
| 2023 Novembro | 11 | 17 | 28 |
| 2023 Outubro | 2 | 8 | 10 |
